Avalo Therapeutics - Public Comps and Valuation Multiples

Avalo Therapeutics Overview

About Avalo Therapeutics

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Founded

2011

HQ

Employees

Website

avalotx.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

Last FY Revenue $0.4M

Last FY EBITDA -$68.3M

EV

$153M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Avalo Therapeutics Financials

In the same period, Avalo Therapeutics achieved -$84.4M in LTM net income.

See Avalo Therapeutics valuation multiples based on analyst estimates

Avalo Therapeutics P&L

In the most recent fiscal year, Avalo Therapeutics reported revenue of $0.4M and EBITDA of -$68.3M.

Avalo Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Avalo Therapeutics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	n/a	XXX	$0.4M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$0.8M	XXX	XXX	XXX
Gross Margin	n/a	XXX	183%	XXX	XXX	XXX
EBITDA	n/a	XXX	-$68.3M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-15497%	XXX	XXX	XXX
EBIT	-$72.1M	XXX	-$68.5M	XXX	XXX	XXX
EBIT Margin	n/a	XXX	-15536%	XXX	XXX	XXX
Net Profit	-$84.4M	XXX	-$35.1M	XXX	XXX	XXX
Net Margin	n/a	XXX	-7966%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Avalo Therapeutics including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Avalo Therapeutics achieved $0.4M in revenue and -$68.3M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	n/a	Analyst estimates available to subscribers	$0.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$0.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	183.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	-$68.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	-15497.3% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$72.1M	Analyst estimates available to subscribers	-$68.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	n/a	Analyst estimates available to subscribers	-15535.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$84.4M	Analyst estimates available to subscribers	-$35.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	n/a	Analyst estimates available to subscribers	-7965.8% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Avalo Therapeutics

This financial data table provides comprehensive performance metrics for Avalo Therapeutics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Avalo Therapeutics reported $0.4M in total revenue.
Fiscal year EBITDA was -$68.3M.
The company maintained a gross profit margin of 183.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was -15497.3%.
Net profit margin reached -7965.8% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Avalo Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Avalo Therapeutics Stock Performance

Avalo Therapeutics has current market cap of $264M, and EV of $153M.

Market Cap Evolution

Avalo Therapeutics Stock Data

As of February 25, 2026, Avalo Therapeutics's stock price is $14.

See Avalo Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$153M	$264M	XXX	XXX	XXX	XXX	$-6.63

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Avalo Therapeutics Valuation Multiples

Avalo Therapeutics's trades at 346.4x EV/Revenue multiple, and -2.2x EV/EBITDA.

See valuation multiples for Avalo Therapeutics and 15K+ public comps

Avalo Therapeutics Financial Valuation Multiples

As of February 25, 2026, Avalo Therapeutics has market cap of $264M and EV of $153M.

Equity research analysts estimate Avalo Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Avalo Therapeutics has a P/E ratio of -3.1x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$264M	XXX	$264M	XXX	XXX	XXX
EV (current)	$153M	XXX	$153M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	346.4x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-2.2x	XXX	XXX	XXX
EV/EBIT	-2.1x	XXX	-2.1x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-3.1x	XXX	-3.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-3.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Avalo Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Avalo Therapeutics Margins & Growth Rates

Avalo Therapeutics's revenue per employee in the last FY averaged $19K, while opex per employee averaged $3.0M for the same period.

Avalo Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Avalo Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Avalo Therapeutics and other 15K+ public comps

Avalo Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$19K	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$3.0M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	179%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	11809%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	15719%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial